Iris Parent Holding CORP Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE: Liminatus Pharma Schedule 13D Filing
Valetudo Therapeutics LLC and Chris Kim jointly file Schedule 13D, reporting beneficial ownership of 14.3% of Liminatus Pharma's common stock.
NASDAQ
SCHEDULE 13D: Iris Acquisition Holdings Discloses 26.5% Stake in Liminatus Pharma Following Business Combination
Iris Acquisition Holdings LLC has filed a Schedule 13D, revealing a 26.5% beneficial ownership stake in Liminatus Pharma, Inc. following the completion of a business combination.
NASDAQ
SCHEDULE 13D: Valetudo Therapeutics and CEO Chris Kim Disclose 23.7% Stake in Newly Formed Liminatus Pharma Post-Merger
Valetudo Therapeutics LLC and its CEO, Chris Kim, have filed a Schedule 13D, revealing a significant 23.7% beneficial ownership in Liminatus Pharma, Inc. following the recent business combination.